SLC5A2 and heart failure: In particular, SGLT2 inhibitors induce robust benefits with regard to reducing heart failure hospitalization with and without atherosclerotic cardiovascular diseases or a prior history of heart failure (Zelniker et al., 2019), suggesting an important role of the diuretic property of SGLT2 inhibition.